Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 2238 |
| PDBID: | 6GKD |
| Chains: | S_R |
| Organism: | Homo sapiens, Lama glama |
| Method: | XRD |
| Resolution (Å): | 2.99 |
| Reference: | 10.1038/s41467-019-10714-y |
| Antibody | |
| Antibody: | D12 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Cystic fibrosis transmembrane conductance regulator |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: S
Mutation: NULL
| >6GKD_S|Chain B, E[auth G], H[auth J], K[auth M], N[auth P], Q[auth S]|Nanobody D12|Lama glama (9844) QVQLQESGGGLVQAGSSLRLACAATGSIRSINNMGWYRQAPGKQRGMVAIITRVGNTDYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTATYYCHAEITEQSRPFYLTDDYWGQGTQVTVSSAAAHHHHHHGAAEQKLISEEDLNGAA |
Antigen
Chain: R
Mutation: NULL
| >6GKD_R|Chain A, D[auth F], G[auth I], J[auth L], M[auth O], P[auth R]|Cystic fibrosis transmembrane conductance regulator|Homo sapiens (9606) SLTTTEVVMENVTAFWEEGGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMG |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| S: ASN32 ASN33 TYR37 ARG45 GLY46 MET47 ILE50 THR52 ASN56 ASP58 TYR59 ASP61 LYS64 HIS96 PRO105 PHE106 TYR107 LEU108 THR109 ASP110 ASP111 TRP113 R: ALA457 GLY458 SER459 SER549 GLY550 GLY551 GLN552 ARG555 PHE575 GLY576 TYR577 LEU578 ASP579 VAL580 LEU581 SER605 LYS606 MET607 GLU608 ILE618 HIS620 LEU636 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
